Sangamo Therapeutics, Inc. Common Stock
SGMOSangamo Therapeutics, Inc. (SGMO) is a biotechnology company specializing in gene editing and gene therapy technologies. Founded in 1995, the company focuses on developing genomic medicines to treat and potentially cure genetic diseases, hemophilia, and cell and gene therapy applications. Sangamo utilizes its proprietary zinc finger nuclease (ZFN) platform to engineer precise genomic modifications, aiming to advance innovative treatments across multiple therapeutic areas.
Company News
The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target...
U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.
The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.
The global mucopolysaccharidosis treatment market is expected to grow significantly, driven by advancements in biotechnology, improved diagnostic techniques, and increased awareness of rare diseases. The market is projected to reach $5,014.5 million by 2035, growing at a CAGR of 5.9%.
Sangamo Therapeutics regained rights to its hemophilia gene therapy after Pfizer terminated their collaboration. The Phase 3 trial met its objectives, but Sangamo was surprised and disappointed by Pfizer's decision to end the partnership.
